SCHEMBL1364240

SCHEMBL1364240

Cc1c(C(=O)N[C@H](c2ccc(F)c(F)c2)C2CCC2)c2cccc(F)c2c(=O)n1Cc1ncco1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 7/20 0.42
WDR5 P61964 10/20 0.38
CYP2C9 P11712 1/20 0.36
PDE2A O00408 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1366190 0.93 CYP2C9 (0.43) S1PR3WDR5CYP2C9
SCHEMBL1364113 0.93 S1PR3 (0.37) S1PR3WDR5CYP2C9
SCHEMBL1364329 0.92 S1PR3 (0.38) S1PR3WDR5CYP2C9
SCHEMBL1365007 0.90 CYP2C9 (0.46) S1PR3WDR5CYP2C9
SCHEMBL1365800 0.90 TACR3 (0.39) S1PR3WDR5CYP2C9
SCHEMBL25795467 0.83 CYP2C9 (0.39) S1PR3WDR5CYP2C9PDE2A
SCHEMBL3345533 0.82 S1PR3 (0.36) S1PR3WDR5PDE2A
SCHEMBL12151111 0.81 S1PR3 (0.36) S1PR3
SCHEMBL1366048 0.80 CYP2C9 (0.38) S1PR3WDR5CYP2C9
SCHEMBL2306426 0.80 CYP2C9 (0.35) S1PR3WDR5CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US claimed
US-20160220555-A1 Method For Treating Or Preventing Hot Flushes IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) 2016-08-04 US disclosed
US-20160220555-A1 Method For Treating Or Preventing Hot Flushes IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) 2016-08-04 US disclosed
US-8415373-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-04-09 US disclosed
US-8415373-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-04-09 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220555-A1 Method For Treating Or Preventing Hot Flushes KLK5, KISS1R, KLKB1 S1PR3 114/4885WDR5 1948/4885CYP2C9 1869/4885
US-20110288120-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNK3, KCNQ3, KCNN3 S1PR3 559/4885WDR5 3400/4885CYP2C9 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.